Current Value
$154.941 Year Return
Current Value
$154.941 Year Return
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
GLDM | -0.12% | $15.83B | 0.1% |
OILK | -0.12% | $71.89M | 0.69% |
SGOL | 0.25% | $5.22B | 0.17% |
IAU | 0.34% | $47.14B | 0.25% |
IGOV | -0.41% | $1.21B | 0.35% |
IBND | 0.45% | $378.69M | 0.5% |
AAAU | 0.56% | $1.56B | 0.18% |
OUNZ | 0.60% | $1.74B | 0.25% |
GLD | 0.60% | $101.85B | 0.4% |
USO | -0.64% | $1.18B | 0.6% |
LDUR | 0.82% | $929.55M | 0.5% |
BAR | 0.82% | $1.12B | 0.1749% |
DBC | 1.02% | $1.22B | 0.87% |
FMF | 1.16% | $155.81M | 0.95% |
CANE | -1.18% | $10.44M | 0.29% |
BNO | -1.22% | $103.68M | 1% |
STOT | 1.31% | $253.88M | 0.45% |
IBTI | 1.34% | $1.06B | 0.07% |
DBE | -1.36% | $52.44M | 0.77% |
PDBC | 1.37% | $4.39B | 0.59% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
TDUP | -15.87% | $880.94M | +338.24% | 0.00% |
AIFU | -14.83% | $6.13B | +82.50% | 0.00% |
HUSA | -10.72% | $22.94M | -6.82% | 0.00% |
DFDV | -9.32% | $247.94M | +1,821.34% | 0.00% |
AQB | -8.82% | $2.84M | -54.35% | 0.00% |
STG | -8.64% | $29.06M | -28.79% | 0.00% |
LITB | -7.71% | $21.70M | -78.27% | 0.00% |
EDSA | -7.41% | $14.40M | -52.10% | 0.00% |
GALT | -7.25% | $147.47M | +3.10% | 0.00% |
CARV | -7.20% | $8.52M | +19.23% | 0.00% |
MVO | -6.43% | $66.13M | -38.96% | 21.90% |
K | -6.26% | $27.41B | +36.96% | 2.88% |
VHC | -4.91% | $45.90M | +59.26% | 0.00% |
APRE | -4.54% | $9.27M | -58.85% | 0.00% |
AGL | -4.51% | $956.23M | -64.68% | 0.00% |
BTCT | -4.05% | $18.98M | +37.85% | 0.00% |
CIG.C | -3.84% | $2.64B | +19.84% | 0.00% |
VSA | -3.19% | $8.67M | -15.70% | 0.00% |
IRWD | -3.09% | $118.27M | -88.79% | 0.00% |
RLX | -3.00% | $2.02B | +20.65% | 0.45% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
RSPH | 65.18% | $731.31M | 0.4% |
KNG | 62.15% | $3.73B | 0.75% |
NOBL | 62.11% | $11.27B | 0.35% |
XLV | 61.44% | $34.14B | 0.09% |
FHLC | 61.33% | $2.43B | 0.084% |
IYH | 61.19% | $2.71B | 0.39% |
PPH | 60.96% | $614.42M | 0.36% |
SDY | 60.82% | $19.79B | 0.35% |
VHT | 60.71% | $15.31B | 0.09% |
IXJ | 60.50% | $3.74B | 0.41% |
FVD | 60.10% | $8.94B | 0.61% |
IHE | 59.98% | $557.07M | 0.39% |
SPHD | 58.51% | $3.14B | 0.3% |
FTCS | 58.48% | $8.31B | 0.52% |
FXH | 58.39% | $898.02M | 0.62% |
MOAT | 57.90% | $12.59B | 0.47% |
SPYD | 57.80% | $6.80B | 0.07% |
SPLV | 57.28% | $7.59B | 0.25% |
BBH | 57.22% | $329.82M | 0.35% |
LGLV | 57.12% | $1.09B | 0.12% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
TH | -0.06% | $712.44M | -17.68% | 0.00% |
HIMS | 0.07% | $11.06B | +144.73% | 0.00% |
CRVO | -0.07% | $52.65M | -64.66% | 0.00% |
USM | 0.07% | $5.32B | +12.04% | 0.00% |
NGVC | -0.18% | $900.11M | +85.00% | 1.17% |
MVIS | -0.20% | $284.16M | +7.55% | 0.00% |
OKLO | 0.22% | $8.08B | +552.42% | 0.00% |
SXC | 0.23% | $692.45M | -16.53% | 5.56% |
MYGN | -0.34% | $483.93M | -78.54% | 0.00% |
RLMD | -0.34% | $20.25M | -79.67% | 0.00% |
NEUE | 0.40% | $61.96M | +27.57% | 0.00% |
NEXT | 0.50% | $2.27B | +9.45% | 0.00% |
UEC | 0.51% | $2.98B | +11.65% | 0.00% |
CCEC | 0.52% | $1.02B | +3.91% | 2.61% |
PHYS | -0.56% | - | - | 0.00% |
KROS | -0.56% | $547.90M | -70.48% | 0.00% |
MSB | 0.57% | $327.87M | +45.04% | 29.70% |
NINE | 0.57% | $29.65M | -58.33% | 0.00% |
ALAR | 0.69% | $90.19M | -69.19% | 0.00% |
SLE | 0.71% | $4.00M | -85.88% | 0.00% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
VIXY | -37.54% | $165.69M | 0.85% |
TAIL | -35.39% | $99.76M | 0.59% |
IVOL | -23.04% | $349.27M | 1.02% |
CLIP | -19.83% | $1.52B | 0.07% |
FXY | -14.00% | $815.67M | 0.4% |
ULST | -13.68% | $662.59M | 0.2% |
TPMN | -13.04% | $30.81M | 0.65% |
FTSD | -11.21% | $231.79M | 0.25% |
SHYM | -10.09% | $350.04M | 0.35% |
XONE | -10.04% | $585.86M | 0.03% |
BTAL | -9.93% | $296.79M | 1.43% |
SPTS | -9.19% | $5.78B | 0.03% |
WEAT | -8.72% | $117.15M | 0.28% |
BIL | -7.95% | $42.87B | 0.1356% |
KCCA | -7.79% | $105.63M | 0.87% |
FXE | -7.47% | $568.58M | 0.4% |
TBLL | -7.36% | $2.13B | 0.08% |
UDN | -7.00% | $147.88M | 0.78% |
BILZ | -6.29% | $827.49M | 0.14% |
GBIL | -6.14% | $6.38B | 0.12% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
IDXX | 55.15% | $42.73B | +9.06% | 0.00% |
VLTO | 53.54% | $25.05B | +5.87% | 0.40% |
NSA | 52.82% | $2.43B | -22.80% | 7.15% |
MTD | 52.77% | $24.62B | -15.24% | 0.00% |
CUBE | 52.70% | $9.66B | -6.20% | 4.88% |
ECL | 52.58% | $75.83B | +12.37% | 0.95% |
IQV | 52.54% | $27.24B | -25.53% | 0.00% |
EXR | 52.32% | $30.95B | -6.14% | 4.46% |
TMO | 51.80% | $154.12B | -26.17% | 0.40% |
FRT | 51.11% | $8.17B | -6.25% | 3.48% |
MA | 50.62% | $499.72B | +24.74% | 0.51% |
BIIB | 50.51% | $18.47B | -45.61% | 0.00% |
A | 50.48% | $33.85B | -8.07% | 0.81% |
EPR | 50.42% | $4.38B | +37.09% | 6.01% |
AMGN | 50.40% | $149.01B | -11.30% | 3.34% |
TECH | 50.34% | $8.13B | -27.65% | 0.62% |
SYK | 50.21% | $150.40B | +15.67% | 0.83% |
PSA | 50.20% | $50.85B | +0.78% | 4.17% |
WAT | 49.93% | $20.97B | +21.47% | 0.00% |
WY | 49.86% | $18.75B | -8.95% | 3.16% |
Yahoo
PARSIPPANY, N.J., July 01, 2025--Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Tuesday, August 5, 2025. Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Wetteny Joseph will review second quarter 2025 financial results and respond to questions from financial analysts during the call.
Finnhub
Zoetis Inc. dropped from Russell 1000 Dynamic Index...
SeekingAlpha
Merck remains a top Big Pharma name with strong leadership, rising sales, and high margins, despite regulatory fears and pressures. Learn why MRK stock is a buy.
Yahoo
The average brokerage recommendation (ABR) for Zoetis (ZTS) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
Yahoo
Zoetis delivered revenue and adjusted EPS above Wall Street expectations in Q1, driven by strong organic operational growth across its diverse portfolio. Management pointed to particularly robust performance internationally, with the Simparica, dermatology, and osteoarthritis pain franchises fueling momentum. CEO Kristin Peck highlighted, “our innovative companion animal portfolio grew 9% operationally, fueled by sustained demand for our diverse, market-leading franchises.” Despite ongoing macro
Yahoo
Zoetis Inc. (NYSE:ZTS) is one of the 10 Worst Aggressive Growth Stocks to Buy According to Short Sellers. On June 18, Stifel analyst Jonathan Block downgraded Zoetis Inc. (NYSE:ZTS)’s stock to “Hold” from “Buy,” reducing the price objective to $160 from $165. The firm warned that revenue growth might fall short of Wall Street expectations over the […]
Double maintains 12 strategies that include ZTS - Zoetis, Inc.